Silence Therapeutics Plc ADR (SLN) Stock Price, Quote & News

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elev...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3457 6900

Website: www.silence-therapeutics.com

Address:

12 Hammersmith Grove, London, United Kingdom

MurrayKummer360 Aug. 19 at 9:09 AM

$PSFE $ATAI $SLN $PR Paysafe remains tied to digital-payments adoption, atai Life Sciences remains focused on psychedelic and mental-health research, SLN remains clinical-stage and speculative, and PR remains execution-dependent. I'm watching payment volumes, clinical data, funding, and liquidity.

0 · Reply

laaarsas Aug. 19 at 8:18 AM

$SLN REALISE THIS IS GOING TO 25!!!!

0 · Reply

laaarsas Aug. 18 at 6:36 PM

$SLN this should go up so much

0 · Reply

laaarsas Aug. 18 at 7:39 AM

$SLN TRENDING MFS THIS IS BIG THIS IS BIG!!!

0 · Reply

nnnuuu Aug. 18 at 6:59 AM

$SLN averaged up on that recent dip post-offering, seeing the PV data in the flesh and with upcoming (really, imminent) lp(a) optionality gives me confidence topping up at these levels.

0 · Reply

JeremyDanie Aug. 18 at 1:51 AM

$SLN

0 · Reply

laaarsas Aug. 17 at 11:11 PM

$SLN CLIMB AND DANCE MFS. CLIMB AND DANCE

0 · Reply

laaarsas Aug. 17 at 4:12 PM

$SLN 14 BROKEN MOTHERFUCKERS

0 · Reply

laaarsas Aug. 16 at 11:05 PM

$SLN FUCKERS PUMP IT

0 · Reply

laaarsas Aug. 16 at 1:50 PM

$SLN PUMP THIS SHIT

0 · Reply

Silence Therapeutics 13M share Secondary priced at $13.50

2026-08-17T10:17:13.000Z - 2 days ago

Silence Therapeutics 13M share Secondary priced at $13.50

Aug 14, 2026, 4:55 PM EDT - 4 days ago

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

Aug 11, 2026, 11:20 PM EDT - 7 days ago

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

2026-08-11T12:00:15.000Z - 8 days ago

Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley

2026-08-10T20:35:32.000Z - 8 days ago

Silence Therapeutics files to sell $150M in ADS’s

Aug 10, 2026, 4:01 PM EDT - 8 days ago

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Silence Therapeutics Transcript: Study result

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Silence Therapeutics Press release: Study result

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Silence Therapeutics Slides: Study result

2026-08-10T11:40:39.000Z - 9 days ago

Silence announces results from Phase 2 SANRECO trial met primary endpoint

Aug 10, 2026, 7:30 AM EDT - 9 days ago

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

2026-08-10T11:20:17.000Z - 9 days ago

Silence Therapeutics reports Q2 EPS (9c), consensus (17c)

Aug 10, 2026, 7:15 AM EDT - 9 days ago

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Silence Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Silence Therapeutics Quarterly report: Q2 2026

Aug 9, 2026, 5:00 PM EDT - 9 days ago

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

2026-07-14T20:35:20.000Z - 5 weeks ago

Silence Therapeutics participates in a conference call with Cantor

2026-07-14T20:05:16.000Z - 5 weeks ago

Silence Therapeutics participates in a conference call with William Blair

2026-06-24T10:55:08.000Z - 2 months ago

Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight

2026-06-24T10:10:31.000Z - 2 months ago

Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald

Jun 23, 2026, 7:00 AM EDT - 2 months ago

Silence Therapeutics Slides: Corporate presentation

2026-06-11T11:36:45.000Z - 2 months ago

Silence Therapeutics highlights follow-up data on divesiran at EHA 2026

Jun 11, 2026, 7:30 AM EDT - 2 months ago

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Jun 3, 2026, 4:55 PM EDT - 2 months ago

Silence Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

May 19, 2026, 2:00 PM EDT - 3 months ago

Silence Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-18T20:16:33.000Z - 3 months ago

Silence Therapeutics files $300M ordinary shares offering

May 18, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Registration statement: Registration filing

May 12, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

2026-05-08T08:30:11.000Z - 3 months ago

Silence Therapeutics price target lowered to $27 from $35 at Chardan

2026-05-07T13:21:52.000Z - 3 months ago

Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year

May 7, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

May 7, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

Silence Therapeutics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Silence Therapeutics Proxy statement: Proxy filing

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Annual report: Q4 2025

2025-12-15T13:20:39.000Z - 8 months ago

Silence Therapeutics CEO Craig Tooman to end employment

Dec 15, 2025, 8:13 AM EST - 8 months ago

Silence Therapeutics Announces Leadership Changes

Nov 19, 2025, 8:00 AM EST - 9 months ago

Silence Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

2025-11-06T14:06:04.000Z - 10 months ago

Silence Therapeutics reports Q3 EPS (15c), consensus (21c)

Nov 6, 2025, 7:30 AM EST - 10 months ago

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 10 months ago

Silence Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:30 AM EST - 10 months ago

Silence Therapeutics Earnings release: Q3 2025

2025-10-23T11:41:01.000Z - 10 months ago

Silence Therapeutics completes patient enrollment in SANRECO

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Sep 9, 2025, 5:35 PM EDT - 1 year ago

Silence Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics to Participate in September Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Silence Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Silence Therapeutics Earnings release: Q2 2025

Jun 12, 2025, 4:01 PM EDT - 1 year ago

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

May 16, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Proxy statement: Proxy Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 7:00 AM EDT - 1 year ago

Silence Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Silence Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Proxy statement: Proxy Filing

May 6, 2025, 7:45 AM EDT - 1 year ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Mar 12, 2025, 1:00 PM EDT - 1 year ago

Silence Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Slides: Q4 2024

Feb 27, 2025, 7:30 AM EST - 1 year ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Dec 9, 2024, 7:30 AM EST - 1 year ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Dec 4, 2024, 10:00 AM EST - 1 year ago

Silence Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 2:00 AM EST - 1 year ago

Silence Therapeutics Earnings release: Q3 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Silence Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 2:30 PM EST - 1 year ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 13, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Sep 30, 2024, 9:00 AM EDT - 2 years ago

Silence Therapeutics Transcript: Chardan Genetic Medicines Conference

Sep 17, 2024, 10:20 AM EDT - 2 years ago

Silence Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 11:30 AM EDT - 2 years ago

Silence Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 5:35 PM EDT - 2 years ago

Silence Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 27, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q2 2024

Aug 15, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Transcript: Study Result

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Press release: Study Result

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Slides: Study Result

Jun 27, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 20, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

May 30, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 16, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024, 7:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q1 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Registration statement: Registration Filing

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 29, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 8, 2024, 11:48 AM EDT - 2 years ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings Call Transcript: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Annual report: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Slides: Q4 2023

Mar 13, 2024, 7:05 AM EDT - 2 years ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Feb 28, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 23, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 5, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Jan 31, 2024, 7:00 AM EST - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 1, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Nov 14, 2023, 7:00 AM EST - 3 years ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 7:00 AM EST - 3 years ago

Silence Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 12:00 PM EST - 3 years ago

Silence Therapeutics Transcript: Study Update

Nov 8, 2023, 7:00 AM EST - 3 years ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 1, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Sep 26, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 11, 2023, 9:20 AM EDT - 3 years ago

Silence Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Reports Second Quarter 2023 Results

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Earnings release: Q2 2023

MurrayKummer360 Aug. 19 at 9:09 AM

0 · Reply

laaarsas Aug. 19 at 8:18 AM

$SLN REALISE THIS IS GOING TO 25!!!!

0 · Reply

laaarsas Aug. 18 at 6:36 PM

$SLN this should go up so much

0 · Reply

laaarsas Aug. 18 at 7:39 AM

$SLN TRENDING MFS THIS IS BIG THIS IS BIG!!!

0 · Reply

nnnuuu Aug. 18 at 6:59 AM

$SLN averaged up on that recent dip post-offering, seeing the PV data in the flesh and with upcoming (really, imminent) lp(a) optionality gives me confidence topping up at these levels.

0 · Reply

JeremyDanie Aug. 18 at 1:51 AM

$SLN

0 · Reply

laaarsas Aug. 17 at 11:11 PM

$SLN CLIMB AND DANCE MFS. CLIMB AND DANCE

0 · Reply

laaarsas Aug. 17 at 4:12 PM

$SLN 14 BROKEN MOTHERFUCKERS

0 · Reply

laaarsas Aug. 16 at 11:05 PM

$SLN FUCKERS PUMP IT

0 · Reply

laaarsas Aug. 16 at 1:50 PM

$SLN PUMP THIS SHIT

0 · Reply

laaarsas Aug. 15 at 11:35 PM

$SLN motherfuckers bid this shit up donkeys ffs wtf is this? We traded at 12+ before best in disease data and now this?

1 · Reply

vcaelum Aug. 15 at 9:14 AM

$FAMI FAMI holding into next week and loading more on monday PM 2.44M shares short and only 1.72 days to cover Quiet days are when I like to load 🤫🤫 $SMJF $SLN

1 · Reply

Zephix Aug. 13 at 10:41 PM

$VERI $SLN Van1

0 · Reply

LongBullish Aug. 13 at 4:41 PM

$TISI $MU $SLS $SLN Team Inc (TISI) has a highly constrained public float of just ~2.64 million shares. Because the massive Stellex block transaction merely transferred existing shares between major funds rather than printing new equity, NO DILUTION occurred. The sudden influx of daily market orders continues to trigger a localized supply squeeze, forcing market makers to consistently raise their ask prices to clear volume.

1 · Reply

GenralP Aug. 13 at 1:17 PM

$SLN so what just happened with increased share count? New to this if somebody would care to explain the implications of this, and what to expect going forward. Thanks!

1 · Reply

kshonstocks Aug. 13 at 12:32 PM

$SLN https://x.com/positivetopline/status/2086780641958322277?s=12&t=P4vqGO0abe5PjKIGEU2xmQ

0 · Reply

kshonstocks Aug. 12 at 9:42 PM

$SLN crazy cheap down here onthat phase 2 data

1 · Reply

itsBTK Aug. 12 at 1:49 PM

$TISI Super thin float. Lets gooo $MU $SLS $SLN

1 · Reply

kshonstocks Aug. 12 at 1:15 PM

$SLN off of offering working

1 · Reply

DonCorleone77 Aug. 12 at 11:23 AM

$SLN Silence Therapeutics 13M share Secondary priced at $13.50 Jefferies, Morgan Stanley, Cantor Fitzgerald and William Blair acted as joint book running managers for the offering.

0 · Reply

laaarsas Aug. 12 at 8:00 AM

$SLN I think the offering seems ok

0 · Reply

stockwitsuser2449 Aug. 12 at 6:29 AM

$SLN summarized by AI Share-count increase: 38.889m ÷ 141.704m = 27.45% Economic dilution to existing shareholders: 38.889m ÷ 180.593m = 21.53% The company is raising approximately $175M gross at $13.50/ADS. Since the ADS represents three ordinary shares, the effective price is $4.50 per ordinary share

0 · Reply

Market Cap	677.99M
Revenue (ttm)	560,000.00
Net Income (ttm)	-88.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15,823.21%
Debt to Equity Ratio	0.00

Volume	1,487,500
Avg Vol	1,093,584
Day's Range	N/A - N/A
Shares Out	47.25M
Stochastic %K	45%
Beta	1.39
Analysts	Strong Sell
Price Target	$34.60